Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Summary of results with 95% bias-corrected bootstrap confidence intervals

From: Breast cancer tumor growth estimated through mammography screening data

  With supposed higher background incidence due to increased hormone therapy use (+21%) Combined estimate (50 to 69 years) with non-adjusted background incidence
  Women aged 50 to 59 years Women aged 60 to 69 years Combined estimate (50 to 69 years)  
Time taken from 10 mm to 20 mm (years)     
   Mean 1.4 (1.1, 1.5) 2.1 (1.8, 2.4) 1.7 (1.5, 1.8) 2.0 (1.8, 2.2)
   Standard deviation 1.9 (1.7, 2.2) 2.4 (2.1, 2.7) 2.2 (2.0, 2.4) 2.7 (2.5, 2.9)
Volume doubling time at 15 mm (days)     
   25th percentile 29 (19, 36) 65 (47, 79) 41 (32, 48) 29 (21, 35)
   50th percentile 73 (56, 86) 143 (116, 165) 99 (84, 111) 94 (77, 107)
   75th percentile 180 (148, 205) 308 (253, 352) 234 (204, 259) 287 (243, 322)
Screening test sensitivity     
   5 mm 29 (21, 36) 24 (18, 30) 26 (22, 31) 26 (22, 31)
   10 mm 92 (88, 99) 91 (86, 98) 91 (88, 96) 91 (87, 96)
Indicators of potential screening efficacy     
   Mean sojourn time (years) 2.3 (2.0, 2.6) 3.5 (3.1, 3.9) 2.8 (2.6, 3.1) 3.4 (3.1, 3.6)
   Proportion of tumors visible on screening 0.95 (0.94, 0.96) 0.95 (0.95, 0.96) 0.95 (0.95, 0.96) 0.95 (0.95, 0.96)